Hologic, Inc. is a medical technology company primarily focused on women’s health; it sells medical devices for diagnostics, surgery, and medical imaging.
In late November 2013, activist investor Carl Icahn disclosed a 12.5% stake in the company. Subsequently, the company adopted a poison pill to prevent a hostile takeover. In negotiations with the Company's board of directors, two additional directors backed by Mr. Icahn were added to the board, each managing directors of Icahn holding companies. Icahn considered his investment and intervention into Hologic to have been a success, with his nominees to the board of directors resigning on March 3, 2016 and exiting his position by May 16, 2016.
In 2017, Hologic acquired Westford, Massachusetts-based aesthetic medicine company Cynosure for $1.65 billion.
On November 20, 2019, Hologic announced the divestment of Cynosure to Clayton, Dubilier & Rice for $205 million; this was completed on December 30, 2019. Cynosure had ~825 employees at the time of the divestiture.
In March 2020, Hologic received emergency use authorization from the FDA for a test for 2019-nCoV to help mitigate the COVID-19 pandemic. In May 2020, Hologic received a second emergency use authorization from the FDA for 2019-nCov to increase potential throughput of testing.
In June 2020, Hologic collaborated with Grifols, a global producer of plasma-driven medicines, to increase Spain's testing capacity for COVID-19.
Highest paying job titles at Hologic include Verification Engineer, Software Engineer, and Project Coordinator